Dr. Hagop Youssoufian is a highly experienced physician-scientist with over 25 years of involvement in drug development. He has worked with various entities, ranging from early-stage startups to multinational biotech and pharmaceutical companies. After a successful academic career as a clinician, teacher, and NIH-funded investigator, Dr. Youssoufian held a number of senior roles in clinical and translational science at various organizations, including Bristol-Myers Squibb, Sanofi Aventis, ImClone, Ziopharm Oncology, Progenics, and BIND.

Throughout his career, Dr. Youssoufian has supported or led the development and approval of several significant medicines, including Sprycel, Taxotere, Erbitux, Cyramza, Lartruvo, and Copiktra. He is a respected member of the American Society for Clinical Investigation and has received numerous awards for his contributions to the field of medicine. With over 100 publications to his name, Dr. Youssoufian holds a B.S. in Biology from Boston College and M.Sc./M.D. from the University of Massachusetts Medical School. He completed fellowships at Johns Hopkins, Harvard, and MIT.